Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects >or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

NCT01439347 is registered in ClinicalTrials.gov with Spectrum Pharmaceuticals, Inc as lead sponsor.

NCT NCT01439347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01439347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects >or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Lead sponsor
Spectrum Pharmaceuticals, Inc
Phase
Phase 3
Overall status
Terminated
Start date
March 31, 2012
Completion date
November 30, 2015
Enrollment
26 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all)